Payment overview · 2025
General Payments
$777.49
50 reported records · 14 companies
Healthcare provider profile · identity verified
Patrick Scott Berry, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SCOTTSBORO, AL · NPI 1023671120
Verified facts
What the public records show
CMS Open Payments records show Patrick Scott Berry, M.D. received $777.49 in general payments during 2025 across 50 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Rexulti, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $193.80 | 24.9% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $175.93 | 22.6% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.46 | 11.0% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.10 | 8.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.37 | 5.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.34 | 5.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.99 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.52 | 4.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.84 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.17 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.31 | 2.2% | 1 | 2025 |
| ORPHALAN INC | Unresolved — no canonical attribution shown | $17.02 | 2.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.16 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.48 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $777.49 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $193.80 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $175.93 | 17 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $66.10 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $54.18 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.37 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| CUVRIOR Normalized: cuvrior |
Drug | ORPHALAN INC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 578 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 54 |
| Furosemide | Furosemide | 328 | 51 |
| Potassium Chloride | Potassium Chloride | 295 | 44 |
| Eliquis | Apixaban | 274 | 28 |
| Gabapentin | Gabapentin | 257 | 73 |
| Omeprazole | Omeprazole | 257 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 69 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 233 | 43 |
| Lisinopril | Lisinopril | 224 | 48 |
| Losartan Potassium | Losartan Potassium | 224 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 217 | 37 |
| Trazodone Hcl | Trazodone Hcl | 211 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 160 | 46 |
| Levetiracetam | Levetiracetam | 160 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 40 |
| Montelukast Sodium | Montelukast Sodium | 159 | 29 |
| Famotidine | Famotidine | 156 | 34 |
| Methocarbamol | Methocarbamol | 155 | 34 |
| Baclofen | Baclofen | 143 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 49 |
| Sertraline Hcl | Sertraline Hcl | 142 | 19 |
| Carvedilol | Carvedilol | 138 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 21 |
| Alprazolam | Alprazolam | 126 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 120 | 25 |
| Prednisone | Prednisone | 118 | 43 |
| Metformin Hcl | Metformin Hcl | 114 | 22 |
| Pregabalin | Pregabalin | 110 | 27 |
| Rivastigmine | Rivastigmine Tartrate | 109 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 107 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 19 |
| Diazepam | Diazepam | 105 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 96 | suppressed |
| Torsemide | Torsemide | 93 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 90 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 79 | 15 |
| Meloxicam | Meloxicam | 78 | 17 |
| Brilinta | Ticagrelor | 77 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 21 |
| Mounjaro | Tirzepatide | 75 | 20 |
| Ozempic | Semaglutide | 75 | 19 |
| Finasteride | Finasteride | 72 | suppressed |
| Lorazepam | Lorazepam | 70 | 13 |
| Jardiance | Empagliflozin | 67 | 15 |
| Linzess | Linaclotide | 65 | 16 |
| Metformin Hcl Er | Metformin Hcl | 65 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | suppressed |
| Clonazepam | Clonazepam | 61 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 60 | suppressed |
| Olanzapine | Olanzapine | 60 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 44 |
| Donepezil Hcl | Donepezil Hcl | 59 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 59 | 16 |
| Topiramate | Topiramate | 59 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | suppressed |
| Methylprednisolone | Methylprednisolone | 57 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 33 |
| Simvastatin | Simvastatin | 55 | 13 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 16 |
| Dalfampridine Er | Dalfampridine | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 43 | suppressed |
| Fingolimod | Fingolimod Hcl | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Promethazine Hcl | Promethazine Hcl | 42 | 17 |
| Tramadol Hcl | Tramadol Hcl | 42 | 17 |
| Azithromycin | Azithromycin | 41 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 17 |
| Benztropine Mesylate | Benztropine Mesylate | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | 17 |
| Indapamide | Indapamide | 36 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 17 |
| Glipizide | Glipizide | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 17 |
| Mupirocin | Mupirocin | 32 | 21 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 14 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 18 |
| Risperidone | Risperidone | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 22 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 13 |
| Lamotrigine Er | Lamotrigine | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 11 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 16 | 12 |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $777.49 · 50 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CUVRIOR, Cologuard Collection Kit, FANAPT, GEMTESA, JARDIANCE, Kerendia, Korlym, MOUNJARO, REXULTI, TRELEGY ELLIPTA, Veozah, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error